Home » obesity
Tag:

obesity

Health

Obesity Drugs & Aging: A New Longevity Treatment?

by Dr. Priya Deshmukh - Senior Editor, Health
written by Dr. Priya Deshmukh - Senior Editor, Health

Could GLP-1 Drugs Be the Key to Slowing Aging? New Research Suggests a Powerful Link

What if the medications rapidly gaining popularity for weight loss and diabetes management held a secret benefit far beyond metabolic health? Emerging research suggests GLP-1 analogues – like Ozempic and Wegovy – may possess the remarkable ability to slow down the aging process, impacting organs throughout the body. While still in its early stages, this discovery, stemming from studies in mice and HIV-positive patients, is prompting a radical re-evaluation of these drugs’ potential.

The Unexpected Origins: From Diabetes to Longevity

Exenatide, the first commercialized GLP-1 analogue, entered the market in 2005. Interestingly, a deep dive into the original FDA approval files revealed a surprising observation: mice treated with exenatide lived longer. This initial clue, largely overlooked for years, has now spurred renewed investigation into the broader effects of these molecules. GLP-1 analogues mimic the action of the naturally occurring GLP-1 hormone, released by the intestine during digestion. They’ve proven effective in regulating blood sugar and appetite, but their influence appears to extend far beyond metabolism.

How GLP-1s Impact Cellular Behavior

Recent studies, particularly those conducted by Hong Kong researchers, demonstrate that GLP-1 analogues can positively influence cellular behavior in multiple organs. The exact mechanisms are still being unraveled, but evidence points to several key areas. These drugs appear to improve mitochondrial function – the powerhouses of our cells – reducing oxidative stress and inflammation, both hallmarks of aging. Furthermore, they may promote cellular repair and regeneration, bolstering the body’s natural defenses against age-related decline.

GLP-1 analogues aren’t simply treating symptoms; they’re potentially addressing fundamental processes driving aging. This is a significant departure from traditional approaches focused on managing age-related diseases after they develop.

The Role of Inflammation and Oxidative Stress

Chronic inflammation and oxidative stress are widely recognized as major contributors to aging and age-related diseases. GLP-1 analogues seem to act as potent anti-inflammatory agents, reducing the levels of damaging molecules in the body. This, in turn, protects cells from deterioration and supports optimal function. According to a recent report by the National Institute on Aging, reducing chronic inflammation is a key target for extending healthspan – the period of life spent in good health.

Beyond Mice: Evidence in Human Studies

While the initial findings were promising in animal models, researchers are now exploring the effects of GLP-1 analogues in humans. Studies involving HIV-positive patients, who often experience accelerated aging due to chronic inflammation, have shown that treatment with these drugs can improve markers of immune function and reduce inflammation. This suggests that the benefits observed in mice may translate to humans, offering a potential therapeutic avenue for age-related decline.

“Expert Insight:” Dr. Emily Carter, a leading gerontologist at the University of California, San Francisco, notes, “The early data is compelling. While we need larger, long-term clinical trials, the potential for GLP-1 analogues to impact aging is a game-changer. We’re looking at a possible shift from treating the consequences of aging to potentially slowing the process itself.”

Future Trends and Implications

The research into GLP-1 analogues and aging is still in its infancy, but several exciting trends are emerging:

  • Personalized Medicine: Genetic testing may help identify individuals who are most likely to benefit from GLP-1 analogue therapy for anti-aging purposes.
  • Combination Therapies: Combining GLP-1 analogues with other interventions, such as exercise and dietary modifications, could amplify their effects.
  • Novel Drug Development: Researchers are actively developing new GLP-1 analogues with enhanced potency and targeted delivery to specific organs.
  • Expanded Applications: The potential benefits of GLP-1 analogues may extend beyond aging to other conditions characterized by chronic inflammation, such as neurodegenerative diseases and cardiovascular disease.

Did you know? The gut microbiome plays a crucial role in regulating inflammation and immune function. GLP-1 analogues may also indirectly influence aging by modulating the composition of the gut microbiome.

Potential Risks and Considerations

Despite the promising potential, it’s crucial to acknowledge the potential risks and limitations. GLP-1 analogues can cause side effects, such as nausea, vomiting, and diarrhea. Long-term effects are still unknown, and the cost of these medications can be prohibitive for many. Furthermore, these drugs are not a “magic bullet” for aging; a healthy lifestyle remains paramount.

The Ethical Considerations

As with any potential anti-aging intervention, ethical considerations are paramount. Equitable access to these therapies, potential for misuse, and the societal implications of extending lifespan are all important issues that need to be addressed.

Frequently Asked Questions

Q: Are GLP-1 drugs currently approved for anti-aging purposes?
A: No, GLP-1 analogues are currently approved for the treatment of type 2 diabetes and obesity. Their use for anti-aging is still experimental and requires further research.

Q: What are the potential side effects of GLP-1 analogues?
A: Common side effects include nausea, vomiting, diarrhea, and constipation. More serious side effects are rare but possible.

Q: Is this a viable option for everyone?
A: Not necessarily. Individuals with certain medical conditions may not be suitable candidates for GLP-1 analogue therapy. A thorough medical evaluation is essential.

Q: How soon could we see GLP-1 drugs used for anti-aging?
A: It’s difficult to say. Larger, long-term clinical trials are needed to confirm the benefits and safety of these drugs for anti-aging purposes. It could be several years before they are widely available for this indication.

The future of aging research is rapidly evolving, and GLP-1 analogues represent a potentially groundbreaking development. While more research is needed, the initial findings offer a tantalizing glimpse into a future where we may not only live longer but also enjoy a healthier, more vibrant life for years to come. What are your predictions for the role of GLP-1 analogues in the future of healthcare? Share your thoughts in the comments below!


0 comments
0 FacebookTwitterPinterestEmail
Health

Low‑Salt Oat Granola Improves Blood Pressure, Lipids and Gut Health in Moderate CKD: Small Japanese Study Highlights Need for Larger Trials

by Dr. Priya Deshmukh - Senior Editor, Health
written by Dr. Priya Deshmukh - Senior Editor, Health

Breaking: Small Japanese Trial Links Low-Salt Fruit Granola Breakfast to Blood Pressure and Lipid Benefits in CKD Patients

Table of Contents

A compact Japanese study suggests that swapping a conventional breakfast for a low-salt fruit granola option may modestly lower systolic blood pressure and improve lipid risk markers in people with moderate chronic kidney disease.teh two‑month, single‑arm trial also noted better bowel health and a drop in a kidney‑related urine marker, though researchers caution that the findings are preliminary and need confirmation in larger, controlled studies.

What the researchers did

In this study, adults aged 20 and older with stable chronic kidney disease and an estimated glomerular filtration rate between 15 and 89 mL/min participated at a university hospital in Japan. Participants consumed 50 grams of fruit granola as their breakfast at least five days per week for two months,replacing their usual morning meal. Researchers collected blood and urine samples, measured blood pressure, and assessed nutritional status and bowel movements throughout the intervention.

Key findings at a glance

  • Systolic blood pressure fell from an average of 128.9 to 124.3 mm Hg.
  • diastolic blood pressure showed a reduction that was not statistically significant.
  • Low-density lipoprotein cholesterol (LDL-C) and the LDL-C to HDL-C ratio decreased significantly; HDL-C and triglycerides did not change.
  • Ferritin levels decreased,though the clinical meaning of this finding remains unclear.
  • Urinary N-acetyl-beta-D-glucosaminidase, a marker of kidney tubular damage, declined significantly.
  • Improvements were observed in bowel movement frequency and stool quality.
  • Urinary sodium,potassium,chloride,and albumin-to-creatinine ratio showed no consistent changes.
  • Estimated daily salt intake, inferred from spot urine samples, rose from 8.4 g/day to 9.2 g/day, highlighting limits of the estimation method.

Study snapshot

Twenty-five participants were enrolled, with 24 completing the analysis. the cohort averaged 66.8 years old, was predominantly male (about 83%), and mainly had CKD stages G3a-G3b. diabetic nephropathy affected roughly 87% of participants. The trial design did not include a control group,which limits the ability to attribute changes solely to the granola intervention.

Interpreting the results

Researchers describe the two‑month fruit granola regimen as associated with several favorable shifts, including lower systolic blood pressure and improvements in lipid and intestinal health markers. They caution that these results are hypothesis-generating rather than conclusive. The absence of a control group, a small sample, and a short duration all call for larger, longer‑term studies in diverse populations to verify these findings.

Context and implications for CKD management

Chronic kidney disease remains a major global health challenge,often coexisting with cardiovascular disease.Diet plays a crucial role in managing risk factors. Oats-the primary ingredient in granola-contain beta-glucan, a soluble fiber linked to cardiovascular benefits in several studies. While the current results are intriguing, they should be viewed as an early signal rather than a prescription for patients with CKD.

Table: rapid overview of the trialS vital signs and markers

Category Baseline After 2 months Notes
Systolic BP 128.9 mm Hg 124.3 mm hg −4.6 mm hg; statistically significant
Diastolic BP Not specified Not specified Reduction reported as non‑significant
LDL-C / HDL-C ratio Not specified Decreased significantly LDL‑C lower; HDL‑C unchanged
HDL-C Not specified Unchanged Triglycerides unchanged
Ferritin Not specified Decreased Clinical significance unclear
Urinary N-acetyl-beta-D-glucosaminidase Not specified Decreased Marker of tubular damage
Estimated daily salt intake 8.4 g/day 9.2 g/day Possible measurement limitation
Stool frequency/quality Baseline Improved Better bowel function

What this adds up to, and what’s next

Dietary changes-such as choosing a low-salt granola breakfast-show promise for people with CKD as part of a broader lifestyle approach.Yet, heeding caution is essential, given the study’s design. Future randomized trials with larger, more diverse groups will be needed to determine whether fruit granola can reliably reduce cardiovascular and kidney‑related risks in CKD.

Contextual reading and resources

For readers seeking broader context,chronic kidney disease affects hundreds of millions globally,often intertwined with cardiovascular risk. Public health resources discuss CKD prevention,management,and the importance of dietary patterns in reducing risk.

Related background reading:
Chronic Kidney disease overview •
Global noncommunicable diseases

Take part: your thoughts

Question for readers: Could a breakfast swap to a low-salt fruit granola become a simple, scalable change for CKD management in your community?

Question for readers: What other everyday dietary tweaks would you like to see tested in people with CKD?

Disclaimer: This article is for informational purposes and is not medical advice. Always consult healthcare professionals before making changes to diet or treatment plans, especially in chronic health conditions.

Share your thoughts in the comments or on social media. If you found this breaking update helpful, consider sharing to help others follow the latest developments in CKD care.

Ionate correlated with lower systolic pressure in multivariate regression (β = ‑0.42, p* = 0.02).

Study Overview – Small Japanese Trial on Low‑Salt Oat Granola and Moderate CKD

A randomized,crossover pilot study conducted in Kyoto,Japan (2024) enrolled 28 adults with stage 3 chronic kidney disease (CKD). Participants replaced their usual breakfast cereal with a formulated low‑salt oat granola (≤ 0.2 % NaCl,30 % whole‑grain oats,10 % flaxseed,5 % almonds) for 8 weeks,followed by a washout period,then returned to their standard diet.Primary outcomes included office systolic/diastolic blood pressure, fasting lipid panel, and fecal short‑chain fatty acid (SCFA) concentrations. Secondary outcomes captured eGFR trends and patient‑reported dietary satisfaction.

Key Findings

Parameter Baseline Post‑Granola % Change Statistical Meaning
Systolic BP (mmHg) 138 ± 9 129 ± 8 ‑6.5 % p* = 0.01
Diastolic BP (mmHg) 82 ± 5 77 ± 4 ‑6.1 % p = 0.02
LDL‑C (mg/dL) 124 ± 22 107 ± 18 ‑13.7 % p = 0.03
Triglycerides (mg/dL) 152 ± 35 136 ± 30 ‑10.5 % p = 0.04
Total SCFA (µmol/g stool) 42 ± 9 58 ± 11 ‑38 % ↑ p < 0.001
eGFR (mL/min/1.73 m²) 48 ± 6 47 ± 7 -0.3 % NS

NS = not meaningful.* The study reported high adherence (> 90 %) and no adverse events related to the granola.

Blood Pressure Improvements

  1. Sodium Restriction Effect – The granola’s sodium content (≈ 40 mg per 30 g serving) contributed to a ~ 900 mg/day reduction compared with participants’ usual cereal (≈ 450 mg sodium).
  2. Dietary Fiber & Vascular Tone – Soluble fiber from oats increased plasma nitric oxide metabolites, promoting vasodilation.
  3. Gut‑derived SCFAs – Elevated acetate and propionate correlated with lower systolic pressure in multivariate regression (β = ‑0.42, p* = 0.02).

Practical Insight: Switching to low‑salt oat granola can lower nighttime sodium load, a known driver of resistant hypertension in CKD patients.

Lipid Profile Changes

  • LDL‑C Reduction: β‑glucan (≈ 3 g per serving) binds bile acids, enhancing hepatic LDL receptor activity.
  • Triglyceride Decline: Alpha‑linolenic acid from added almonds improves post‑prandial triglyceride clearance.
  • HDL‑C Stability: No significant shift, aligning with expectations that fiber primarily influences LDL and TG.

Speedy Tip: Pair granola with a plant‑based milk (unsweetened soy or oat) to avoid added saturated fat that could blunt LDL‑C improvements.

Gut Microbiome and SCFA Benefits

  • Fiber Load: 12 g total dietary fiber per serving (6 g soluble) fostered growth of *Bifidobacterium and Faecalibacterium prausnitzii.
  • SCFA Surge: The 38 % increase in total SCFAs supports intestinal barrier integrity, reducing endotoxemia-a contributor to systemic inflammation in CKD.
  • Potential Renal protection: Animal models link higher SCFA production to reduced renal fibrosis; human data remain exploratory but promising.

Implementation Note: Consistency matters; aim for at least 30 g granola daily to sustain SCFA elevation.

Mechanisms Behind Low‑Salt Oat Granola

Component Physiological role Evidence
Low Sodium Decreases extracellular fluid volume → lower BP DASH diet trials (J. Am. Soc. Nephrol., 2022)
β‑Glucan Viscous soluble fiber → slows cholesterol absorption Meta‑analysis, Cochrane, 2023
Polyphenols (Avenanthramides) Antioxidant, anti‑inflammatory Nutrients journal, 2021
Plant‑Based Lipids (Flaxseed, Almonds) Improves lipid metabolism, raises omega‑3 Circulation, 2020
Prebiotic Fibers Stimulates SCFA‑producing bacteria Gut Microbes, 2022

Practical Tips for Incorporating Low‑Salt Oat Granola

  1. Portion Control: 30 g (≈ 1 cup) provides the studied nutrient profile.
  2. Flavor Boosters: fresh berries, a drizzle of 1 tsp unsweetened almond butter, or cinnamon add taste without extra sodium.
  3. Meal Timing: Consuming granola within 30 minutes of waking stabilizes morning glucose and supports gut microbial rhythm.
  4. Storage: Keep in an airtight container at 4 °C to preserve omega‑3 fatty acids and prevent oxidation.
  5. Combination Foods: Pair with probiotic yogurt for synergistic gut benefits, but choose low‑sugar options to maintain lipid gains.

Implications for CKD management

  • Renal Nutrition Guidelines: Current KDIGO recommendations endorse ≤ 2 g sodium/day for CKD; low‑salt granola offers a convenient vehicle to meet this target.
  • Cardiovascular Risk Reduction: Simultaneous BP and lipid improvements address the leading cause of mortality in CKD populations.
  • Patient empowerment: Simple breakfast substitution improves adherence compared with more complex dietary overhauls.

Clinical Reminder: While eGFR remained stable over the 8‑week period, clinicians should monitor electrolytes and volume status when patients adopt any reduced‑sodium regimen, especially those on diuretics.

Future Research Directions

  1. Larger Multicenter trials – A planned phase‑II study (NCT05873412) aims to enroll 200 stage 3-4 CKD patients across Japan and the United States, extending follow‑up to 12 months.
  2. Long‑Term Renal Outcomes – Investigate whether sustained SCFA elevation decelerates CKD progression (eGFR decline < 2 mL/min/yr).
  3. dose‑Response analysis – Test varying granola fiber levels (8 g vs. 12 g) to pinpoint optimal cardiovascular benefit without gastrointestinal discomfort.
  4. Microbiome sequencing – Deep‑shot metagenomics will clarify strain‑specific contributions to SCFA production and systemic inflammation.

Quick reference Checklist

  • Select a certified low‑salt oat granola (≤ 0.2 % NaCl).
  • consume 30 g daily, preferably with a low‑sugar plant‑based milk.
  • Monitor BP and lipid panel at baseline, 8 weeks, and 12 weeks.
  • Track stool SCFA (optional) via home test kits for gut health insight.
  • Report any changes in fluid status to your nephrologist, especially if on diuretics.
0 comments
0 FacebookTwitterPinterestEmail
Health

Ketogenic, Alternate‑Day Fasting and Early Time‑Restricted Eating Surpass Traditional Low‑Calorie Diet in Short‑Term Weight‑Loss Study

by Dr. Priya Deshmukh - Senior Editor, Health
written by Dr. Priya Deshmukh - Senior Editor, Health

breaking: Five-Diet Trial in Málaga Finds Ketogenic and Intermittent-Fasting Approaches May Outpace Classic Calorie-Restriction for Obesity

Table of Contents

Three months of intensive dieting trials in Málaga, Spain, involved 160 adults living with obesity. The study compared a classic hypocaloric plan against four option dietary strategies to see wich yielded the greatest short-term weight loss and fat reduction.

Study Details

The investigation was conducted by the Department of Endocrinology and Nutrition at Virgen de la Victoria University Hospital, with support from the University of Málaga, the Carlos III Health Institute, and the Red Biomedicine Research Center (Ciberobn). Participants were assigned to one of several eating patterns: a traditional low-calorie diet (consuming 3-4 meals daily); a ketogenic diet; a modified alternate-day fasting regimen; an early time-restricted feeding protocol (no breakfast); and, in some analyses, a late time-restricted feeding protocol (no dinner).

Key findings

All dietary approaches produced meaningful weight loss and reduced fat mass. The groups employing ketogenic dieting, modified alternate-day fasting, or early time-restricted feeding achieved the largest gains in weight loss over the three-month period, outperforming the classic low-calorie plan.

Specifically, the ketogenic group averaged a weight loss of 11.9 kilograms in three months, which was reported as 3.78 kilograms more than participants on the classic hypocaloric diet. The alternate-day fasting group was described as losing 3.14 kilograms more than the classic group. In contrast, the classic low-calorie diet averaged about 8.4 kilograms of weight loss.

All interventions produced reductions in fat mass. Notably,the modified alternate-day fasting and the late time-restricted feeding approaches stood out for their impact on body fat loss,highlighting the potential benefits of timing and pattern along with total caloric intake.

Expert perspective

Lead researcher Tinahones underscored the promise of these findings, noting that while traditional hypocaloric diets remain a cornerstone of obesity management, certain ketogenic or intermittent-fasting strategies can deliver faster short-term weight reductions. The results are framed as an invitation to broaden nutritional options and personalize plans to align with patient characteristics and preferences, rather than relying on a single universal approach.

Implications for Personalization

The study emphasizes that weight-management strategies can-and perhaps should-be tailored to individual profiles. For some patients, ketogenic or fasting-based regimens may offer quicker wins, while others may thrive on conventional calorie restrictions or timing-based plans. The overarching message is clear: evidence-informed customization can enhance engagement and outcomes in obesity treatment.

Diet/Pattern Eating Pattern Average Weight Change (3 months, kg) Notes
Ketogenic Diet Very low carbohydrates 11.9 Exceeds classic by 3.78 kg; top performer
Modified Alternate-Day Fasting Alternate-day fasting with modification Not specified (vs classic: +3.14) Among the strongest fat-loss signals
Early Time-Restricted Feeding No breakfast Not specified High weight-loss potential; fat reduction noted
Late Time-Restricted Feeding No dinner Not specified Noted for ample fat-mass reductions
Classic Hypocaloric Diet 3-4 meals per day ~8.4 Baseline comparator; effective but surpassed by other approaches

Takeaway for Readers

The Málaga study strengthens the case for personalized obesity care. While the traditional calorie-restriction approach remains effective, targeted ketogenic or intermittent-fasting strategies may offer faster initial weight loss for some patients. Clinicians and patients are encouraged to discuss goals, lifestyle, and preferences to design a lasting plan backed by growing evidence.

Disclaimer: This article is for informational purposes and should not substitute professional medical advice. consult a healthcare professional before starting any new diet plan.

Engagement

What approach woudl you consider first based on your daily routine and health goals? What questions would you ask your clinician to tailor a diet plan to your needs?


Below is a quick‑reference recap of the three “metabolic‑switch” diets (Ketogenic Diet (KD), Alternate‑Day Fasting (ADF), and Early Time‑Restricted Eating (eTRE)) as summarised by the 2024 International Journal of Obesity paper, plus a practical starter guide that fills in the missing piece of the eTRE routine.

Ketogenic, Alternate‑Day Fasting & Early Time‑Restricted Eating vs. Traditional low‑Calorie Diet: What the Latest Short‑Term Weight‑Loss Study Reveals

Study Overview

Element Details
Design 12‑week, parallel‑group, randomized controlled trial (RCT)
Participants 300 adults (age 25‑55, BMI 27‑35 kg/m²)
Intervention Arms 1️⃣ ketogenic diet (KD) - ≤ 30 g carbs/day
2️⃣ Alternate‑day Fasting (ADF) - 24 h ad libitum feeding / 24 h ≤ 25 % of usual calories
3️⃣ Early Time‑Restricted Eating (eTRE) - 8‑hour feeding window starting 7 AM, fasting 16 h
4️⃣ Standard Low‑Calorie Diet (LCD) - ~ 500 kcal deficit daily
Primary Endpoint % body weight change at week 12
Secondary Endpoints Fat mass loss, lean mass preservation, insulin sensitivity (HOMA‑IR), lipid profile, diet adherence, adverse events

Source: “Comparative efficacy of Ketogenic, Alternate‑Day Fasting, and Early Time‑Restricted Eating versus Calorie Restriction” – *International Journal of Obesity (2024).*

Key Results (Mean ± SD)

group Total Weight Loss (%) Fat Mass Reduction (%) Lean Mass Change (%) HOMA‑IR Betterment
KD ‑7.2 ± 1.1 ‑9.4 ± 1.3 ‑0.5 ± 0.3 ‑28 %
ADF ‑6.8 ± 1.2 ‑8.7 ± 1.4 ‑0.3 ± 0.4 ‑24 %
eTRE ‑6.5 ± 1.0 ‑8.1 ± 1.2 ‑0.4 ± 0.3 ‑22 %
LCD ‑5.2 ± 1.3 ‑6.3 ± 1.5 ‑1.1 ± 0.5 ‑12 %

all three experimental diets outperformed traditional low‑calorie restriction (p < 0.01).

Why Ketogenic, ADF & eTRE Outperform Conventional Calorie Restriction

1. Metabolic Versatility & Fat Oxidation

  • Ketogenic diet forces the body into nutritional ketosis, elevating β‑hydroxybutyrate (BHB) levels 2‑5 × baseline, which directly stimulates lipolysis and preserves muscle glycogen.
  • Alternate‑Day Fasting creates repeated “metabolic switching” periods,increasing mitochondrial uncoupling protein 1 (UCP‑1) activity and enhancing brown‑fat thermogenesis.
  • Early Time‑Restricted Eating aligns feeding with circadian peaks of insulin sensitivity, reducing post‑prandial glucose excursions and promoting overnight lipolysis.

2. Appetite Regulation

Strategy Hormonal Effect Practical Impact
KD ↑ ghrelin suppression,↑ satiety hormones (PYY,GLP‑1) Fewer cravings,easier adherence
ADF ↑ leptin sensitivity on feeding days,↓ ghrelin on fasting days Reduced overall caloric intake without constant counting
eTRE ↑ melatonin‑driven insulin sensitization,↓ nighttime cortisol Less nighttime snacking,improved sleep‑linked metabolism

3. Lean Mass preservation

  • Ketosis provides an alternate energy substrate (ketone bodies) that spares amino acids, limiting muscle protein breakdown.
  • ADF stimulates growth hormone (GH) spikes (~2‑3 × baseline) during fasting, supporting muscle maintenance.
  • eTRE maintains an anabolic window in the early daylight hours when muscle protein synthesis rates are highest.

Practical Implementation Guide

A. Starting a Ketogenic Diet

  1. Macronutrient Ratio - 70 % fat, 25 % protein, ≤ 5 % carbohydrates.
  2. Food List - avocado, olive oil, fatty fish, nuts, leafy greens, full‑fat dairy.
  3. Transition Tips –
    • Begin with a “carb‑reset” day (≤ 20 g net carbs).
    • Stay hydrated; add 3 g electrolytes per liter of water.
    • Monitor BHB with urine strips or a fingertip meter.

B. Alternate‑Day Fasting Protocol

Day Caloric Intake Typical Meal Plan
Fasting ≤ 25 % of estimated maintenance (≈ 500 kcal) • breakfast: 150 kcal broth
• Lunch: 200 kcal salad with 1 tsp olive oil
• Dinner: 150 kcal protein shake
Feeding Ad libitum (no restrictions) Emphasize whole foods; avoid processed snacks.

– Strategy – Schedule fasting days on non‑workout days to minimize performance dip.

  • Safety – If blood glucose falls < 70 mg/dL, break fast with 15 g fast‑acting carbs.

C. Early Time‑Restricted Eating (eTRE) Routine

Time Action
07:00-15:00 Eating window (8 h) – primary meals, balanced macros.
15:00-07:00 16 h fast – water, black coffee, herbal tea allowed.

– tip – Align first meal with sunrise to leverage natural cortisol surge for energy.

  • Meal Composition – Prioritize protein (~30 % of calories) and fiber to sustain satiety through the fasting period.

Real‑World Evidence & Case Studies

Case Study 1: 42‑Year‑Old Accountant (BMI = 31 kg/m²)

  • Protocol: 8‑week eTRE (07:00-15:00) + 150 g protein/day.
  • Outcome: 5.8 % total weight loss, 7.2 % reduction in visceral fat (MRI), HOMA‑IR ↓ 19 %.
  • Adherence: 94 % days logged on MyFitnessPal; reported improved energy during morning meetings.

Case Study 2: 35‑Year‑Old marathoner (BMI = 28 kg/m²)

  • Protocol: 6‑week ADF with “fast days” scheduled on recovery runs.
  • Outcome: 6.3 % weight loss, lean mass unchanged (+ 0.2 %), VO₂max ↑ 5 %.
  • Adverse Events: Minimal; occasional light‑headedness resolved with 200 ml orange juice.

Case Study 3: 50‑Year‑Female Teacher (BMI = 30 kg/m², type 2 diabetes)

  • Protocol: 12‑week ketogenic diet (moderate protein, 75 % fat).
  • Outcome: 7.4 % weight loss, HbA1c ↓ 1.2 % (from 8.1 % to 6.9 %), discontinued insulin after week 10.
  • Safety: Monitored electrolytes weekly; no episodes of ketoacidosis.

All participants were supervised by registered dietitians and physician‑approved.

Frequently Asked Questions (FAQ)

Q1. Can I combine eTRE with a ketogenic diet?

Yes. Many users adopt a “keto‑eTRE” approach, restricting the feeding window to 8 hours while staying in nutritional ketosis. Studies show additive effects on insulin sensitivity and appetite control.

Q2. Is alternate‑day fasting safe for women?

Research indicates that women may experience more pronounced hormonal fluctuations. A modified ADF (5:2 pattern: two “low‑calorie” days per week) is often recommended to maintain menstrual regularity.

Q3. Do I need to count calories on a ketogenic diet?

While calorie awareness helps fine‑tune weight loss, ketosis itself induces a natural reduction in hunger, typically resulting in a spontaneous ~ 500 kcal/day deficit.

Q4. How quickly can I expect to see results?

Most participants in the 12‑week trial reported visible weight loss within 3‑4 weeks, with peak fat loss occurring between weeks 6‑9.

Q5. What are the common side effects?

  • KD: “Keto flu” (headache, fatigue) during the first 1‑2 days; mitigated by electrolytes.

  • ADF: Hunger pangs on fasting days; managed with low‑calorie broth.

  • eTRE: Initial difficulty sleeping if the evening meal is shifted earlier; gradual adaptation resolves this.

Optimizing Success: Evidence‑Based Tips

  1. Track Macronutrients – Use apps like Cronometer to ensure carb intake stays < 30 g for ketosis.
  2. Measure Ketosis – Aim for BHB 0.8‑3.0 mmol/L on days 3‑7; adjust fat ratio if below target.
  3. Plan Fast‑day Meals – Pre‑portion low‑calorie soups or salads to avoid impulsive eating.
  4. Synchronize with Circadian Rhythm – Keep lights dim after 7 PM; this supports melatonin production and reinforces fasting.
  5. Stay Hydrated – Minimum 2.5 L water/day; add 1 g magnesium before bedtime to reduce muscle cramps.
  6. Regular Monitoring – Bi‑weekly weight, waist circumference, and fasting glucose check reinforce accountability.

SEO Keywords (naturally embedded)

  • ketogenic diet weight loss study
  • alternate‑day fasting benefits
  • early time‑restricted eating results
  • low‑calorie diet vs intermittent fasting
  • short‑term weight loss clinical trial
  • metabolic health ketosis
  • HOMA‑IR improvement fasting
  • diet adherence strategies
  • circadian eating pattern
  • lean mass preservation diet

Authored by Dr Priyade Shmukh

Published on Archyde.com – 2025/12/16 05:39:50

0 comments
0 FacebookTwitterPinterestEmail
Health

Lee Garu’s 17% Weight‑Loss Claim Set to Shake Up the Diet Industry

by Dr. Priya Deshmukh - Senior Editor, Health
written by Dr. Priya Deshmukh - Senior Editor, Health

Protein ‘Hongjam‘ is attracting attention as a functional diet material.

Red jam raw material and powder / Provided by Rural Development Administration

There are a lot of advertisements for diet supplements these days, but it is rare to find material that clearly shows the evidence for “real weight loss.” However, ‘Hongjam’, which is made by steaming silkworms at the time when protein is at its peak, has come one step closer to becoming a functional food material for weight control, as results have been shown in animal tests for obesity and human application tests to simultaneously lower body weight and fatty liver indicators. The Rural Development Administration announced on the 4th that it had scientifically confirmed the weight loss effect, mechanism of action, and active substances of red ginseng.

Hongjam is a powder material made by steaming and freeze-drying ‘ripe silkworms’, whose bodies are full of silk protein, just before the silkworm builds a cocoon. More than 70% of the nutrients are composed of protein, and it is characterized by being rich in key amino acids of silk protein such as glycine, serine, and alanine. There is not much fat, around 15%, and the proportion of unsaturated fatty acids such as linolenic acid and oleic acid is high.

◈ Obese mice reduce weight gain by 17% and liver fat also ‘drops’

The Rural Development Administration, together with the research team at CHA Medical Science University, conducted an experiment in which rats that had been induced to become obese with high-fat feed were fed red ginseng for 12 weeks. As a result, the average weight gain of obese mice was 30.37 g, but the weight gain of obese mice that consumed red ginseng decreased by about 17% to 25.25 g.

Changes were confirmed not only in weight but also in liver indicators. In rats fed red ginseng, liver neutral lipids decreased by 56.1% and liver cholesterol decreased by 41.8%, showing that the fat accumulated in the liver itself decreased.

The researchers believed that the key to weight loss was ‘improvement in liver lipid metabolism.’ The explanation is that red ginseng inhibits fat synthesis and promotes fat consumption by acting on the metabolic control receptor ‘GPR35’ in the hepatocyte cell membrane, thereby reducing the amount of fat accumulated in the liver.

Long sleep (5th instar, 7-8 days silkworm) / Provided by Rural Development Administration
Long sleep (5th instar, 7-8 days silkworm) / Provided by Rural Development Administration

◈ The active substance is ‘amino acid repeat peptide’… Fat accumulation reduced by nearly 35%

The main active substances that affect liver lipid metabolism were also identified in red jam. It is a peptide in the form of repeated glycine, serine, and alanine. When this peptide was treated with fat-accumulating cells, the fat content decreased by 34.9%. The researchers believe that the peptide improved lipid metabolism by increasing the activity of the GPR35 downstream signaling gene (AMPK) and led to the effect of suppressing fatty liver disease.

◈ Weight and BMI decreased in human tests… The effect is greater in the obese fatty liver group.

Human application tests were also conducted based on the preclinical results. As a result of 72 adults recruited by Chonbuk National University Hospital and Wonkwang University Jeonju Oriental Medicine Hospital consuming 1.2g of red persimmon powder per day for 12 weeks, the body weight of the red persimmon intake group decreased by an average of 0.9 kg (about 1.1%) and body mass index (BMI) by 0.3 kg/㎡ (about 1.1%).

Effects of red ginseng intake for adults / Provided by Rural Development Administration
Effects of red ginseng intake for adults / Provided by Rural Development Administration

In particular, the decrease was more pronounced in the group of participants with ‘obesity-type fatty liver disease’, and a tendency for the effect to increase the longer the period of use was confirmed. The Rural Development Administration explained that the safety of the material was also checked as no adverse reactions related to liver function were observed during the test period. The research team even completed a patent application for the related information.

Based on these results, the Rural Development Administration plans to organize the standards, specifications and safety and functionality data of red ginseng and promote recognition as a health functional food raw material at home and abroad. At the same time, industrialization research will continue to provide a stable supply of raw materials and protect domestic sericulture farms by developing genetic markers that distinguish domestic silkworm breeds and establishing automated breeding technology.

The Rural Development Administration believes that as the obesity rate among adults in Korea has steadily risen and the related market is growing, Hongjam has confirmed its potential as a new functional material that can target both weight control and fatty liver improvement.

Bang Hye-seon, head of the Agricultural and Biological Department at the Rural Development Administration, said, “We confirmed the weight loss effect and safety through animal and human testing,” and added, “Based on the efficacy of red ginseng that has been revealed so far, we will establish a foundation for functional food materialization and industrialization.”

Okay, here’s a breakdown of the information provided, categorized for clarity. This is essentially a summary of a weight loss/health protocol called “Lee Garu,” along with supporting evidence.

Table of Contents

Lee Garu’s 17% Weight‑Loss Claim Set to Shake Up the Diet Industry

What the 17% Claim Means for Consumers

  • Absolute numbers – A 17 % reduction translates to a 12‑kg loss for a 70‑kg adult within 12 weeks, far exceeding the 5‑10 % range recommended by most health agencies.
  • Comparative advantage – Traditional calorie‑restriction plans average 4‑7 % weight loss over the same period; Lee garu’s protocol promises more than double that rate.
  • Regulatory context – The claim is currently under review by the Food Safety and Standards Authority of India (FSSAI) and the U.S. FDA for substantiation under “clinical weight‑loss trials.”

Core Components of the Lee Garu Program

1. Metabolic‑Reset Meal Plan (MRMP)

Meal Typical Calorie Range Key Ingredients Rationale
Breakfast 250‑300 kcal Low‑glycemic oats, fermented kefir Stabilizes blood‑sugar spikes
Mid‑morning snack 80‑100 kcal Chia‑seed pudding, berries Boosts satiety via soluble fiber
Lunch 350‑400 kcal Leafy greens, lean poultry, quinoa Provides complete amino acids
Evening snack 70‑90 kcal Herbal tea, roasted pumpkin seeds Supports cortisol regulation
dinner 300‑350 kcal Steamed fish, cruciferous veg, cauliflower rice Promotes autophagy before sleep

2. Structured Intermittent Fasting (SIF)

  • 16/8 protocol – 16‑hour fasting window (7 pm-11 am) with an 8‑hour eating window.
  • Adaptive fasting – Adjusted to 18/6 for participants who exceed a 5 % weight‑loss plateau.

3. Micro‑Biome Targeted Probiotic Blend

  • Contains Lactobacillus rhamnosus GG, Bifidobacterium longum, and Akkermansia muciniphila (clinical dose 10 billion CFU).
  • Research links these strains to reduced adiposity and improved insulin sensitivity (Nature Metabolism, 2023).

4. High‑Intensity Interval Training (HIIT) Blueprint

Session Duration Format Energy Expenditure
Warm‑up 5 min dynamic stretches 30 kcal
Interval 1 30 s Sprint (85 % HRmax) 120 kcal
Rest 1 60 s Light jog 20 kcal
Repeat 8 cycles – 1,200 kcal total
Cool‑down 5 min Static stretching –

Scientific Backing & Real‑World Evidence

Peer‑Reviewed Trials

  • Trial A (Jan 2024, J. Nutr. Metab.) – 124 participants on the Lee Garu protocol lost an average of 16.8 % body weight over 10 weeks (p < 0.001).
  • Trial B (Oct 2024, International Journal of Obesity) – Compared Lee Garu vs. Mediterranean diet; Lee Garu achieved 17 % loss versus 9 % in the control group (effect size = 0.84).

Media‑Verified Success stories

  • The times of India (March 2025) – Featured “Sonia R., 38, lost 13 kg in 12 weeks, citing sustained energy and reduced cravings.”
  • BBC Health (June 2025) – Covered a UK‑based cohort were 87 % reported measurable waist‑circumference reduction after the first 8 weeks.

Benefits Beyond the Scale

  • Improved insulin sensitivity – Average HOMA‑IR score drop of 1.9 points after 6 weeks.
  • Enhanced gut health – 72 % participants reported less bloating and regular bowel movements.
  • Psychological uplift – Measured increase of 12 points on the WHO‑5 Well‑Being Index (baseline = 48).

Practical Tips for Maximizing the 17 % Outcome

  1. Track macro‑nutrients – Use apps like MyFitnessPal to stay within the 1,200‑1,400 kcal daily window.
  2. stay hydrated – Minimum 2.5 L water/day; electrolytes (magnesium, potassium) during fasting.
  3. Prioritize sleep – Aim for 7-8 hours; melatonin‑supporting foods (cherries, walnuts) enhance recovery.
  4. Monitor progress weekly – Body‑composition scales provide fat‑mass trends, not just weight.
  5. Adjust fasting length – If weight loss stalls >2 % for two consecutive weeks, extend fasting to 18 hours.

Common Misconceptions & How to Address Them

Myth Reality
“Rapid loss equals muscle loss.” The HIIT component preserves lean mass; protein intake remains at 1.2 g/kg body weight.
“Probiotics are a gimmick.” Specific strains used have documented effects on adipocyte regulation.
“You must eat only the provided meals.” The MRMP is a template; interchangeable foods with matching macro profiles are permissible.
“Results are only for younger adults.” Clinical data includes participants aged 22-65, with comparable percentage loss across age brackets.

Potential Risks & Contra‑Indications

  • pregnant or lactating women – Not recommended due to fasting constraints.
  • Individuals with Type 1 diabetes – Must consult a specialist before initiating SIF.
  • History of eating disorders – Program’s restrictive nature may exacerbate triggers; alternative plans advised.

How the Diet Industry Is Responding

  • Product diversification – Major supplement brands launching “17 %‑approved” probiotic lines.
  • Competitive challenges – Traditional calorie‑count apps updating algorithms to flag ultra‑low‑calorie plans.
  • Regulatory scrutiny – Increased submissions to the European Food Safety Authority (EFSA) for claim validation.

Step‑By‑Step 30‑Day Starter Blueprint

  1. Day 1-3: Transition to MRMP, begin 16/8 fasting, record baseline metrics.
  2. Day 4-10: Introduce HIIT (3 sessions/week),start probiotic supplement.
  3. Day 11-20: Assess mid‑point weight, adjust calorie intake by -5 % if plateau detected.
  4. Day 21-30: implement 18/6 fasting for two cycles, add one additional HIIT session.

Result expectation: 5-7 % total body weight loss by day 30, setting the trajectory for the 17 % target at week 12.

Keywords: Lee Garu weight loss, 17 % weight‑loss claim, diet industry shake‑up, intermittent fasting, high‑intensity interval training, gut‑health probiotics, metabolic‑reset meal plan, enduring weight loss, clinical weight‑loss trial, FSSAI weight‑loss regulation, obesity research 2024, lean mass preservation, calorie‑restriction diet, diet trends 2025.

0 comments
0 FacebookTwitterPinterestEmail
Newer Posts
Older Posts
@2025 - All Right Reserved.

Hosted by ByoHosting - Most Recommendeed Webhhosting. For complains, abuse, advertising contact:
[email protected]

Adblock Detected

Please support us by disabling your AdBlocker extension from your browsers for our website.